Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of targeted therapies to people with cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer. The company is focused on three core areas: counteracting tumor suppressor gene loss, reversing the ability of cancer cells to evade the immune system and identifying novel combinations that will be more effective than single agent therapy
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/10/20 | $60,000,000 | Series B |
Boxer Capital Casdin Capital Cormorant Asset Management | undisclosed |
| 08/18/20 | $50,000,000 | Venture |
Boxer Capital Casdin Capital Cormorant Asset Management Gilead Sciences | undisclosed |
